2026 Interim Report
Filed with HKEX · Stock code 1477 · · 74 pages · English
Corporate Information 2 Financial Summary 4 Corporate Profile 5 Management Discussion and Analysis 7 BUSINESS OVERVIEW 7 FINANCIAL REVIEW 10 Other Information 20 Report on Review of Condensed Consolidated Financial Statements 35 Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 36 Condensed Consolidated Statement of Financial Position 37 Condensed Consolidated State
Ocumension Therapeutics on 6ix
Earlier from Ocumension Therapeutics
- OcuMension acquires rights to Alcon eye drops in exchange for a 16.7% equity stake, signaling the commencement of comprehensive strategic relationship
- OcuMension (01477.HK) Invests Over RMB 123.8 Million in Research, Technology and Self-development Progress in Tandem, Main Product Sales Show Comprehensive Growth
- Ocumension Therapeutics Announces 2023 Interim Results
- Ocumension Therapeutics Announces 2022 Annual Results
- Inside information new drug application of our core product OT-401 approved by the national medical products administration
Later from Ocumension Therapeutics
All Ocumension Therapeutics news releasesFollow Ocumension Therapeutics into a list and get an email when it puts out news.
Follow Ocumension Therapeutics